Microsoft on Monday announced it bought a start-up to boost its artificial intelligence capabilities, and rival Apple confirmed it has boosted its health focus with an acquisition of its own.
Microsoft did not disclose financial terms of its deal to buy Genee, which specializes in using machine smarts to handle the time-sucking task of scheduling meetings.
“Genee uses natural language processing and optimized decisionmaking algorithms, so that interacting with a virtual assistant is just like interacting with a human one,” Outlook and Office 365 corporate vice president Rajesh Jha said in a blog post.
For example, Genee can be copied into an e-mail exchange to act as a virtual assistant of sorts to pin down a time for a business or social meeting.
Jha touted Genee as having designed “an intelligent virtual assistant specialized in the appointment decision.”
The technology was expected to be put to work in Office 365 software that Microsoft offers as a service in the Internet cloud.
The team that started Silicon Valley-based Genee in 2014 will join the Microsoft and the existing service will be discontinued next month, the companies said.
Apple confirmed press reports that it has bought start-up Gliimpse, which uses machine learning as part of its formula for letting people secure, manage and share personal medical information.
“Apple buys smaller technology companies from time to time and we generally do not discuss our purpose or plans,” Apple said in a statement.
Gliimpse offers a unique platform by allowing users to compile medical and health data from different sources, and share as needed with third parties, including doctors.
“We’ve built a magical machine,” Gliimpse said on its Web site. “It takes incomprehensible electronic medical records and turns them into understandable, standardized, coded elements and terminology that both humans and machines can easily understand and use.”
Apple has introduced features and software platforms for its mobile devices to be tools for people to manage and improve health.
OpenAI has warned US lawmakers that its Chinese rival DeepSeek (深度求索) is using unfair and increasingly sophisticated methods to extract results from leading US artificial intelligence (AI) models to train the next generation of its breakthrough R1 chatbot, a memo reviewed by Bloomberg News showed. In the memo, sent on Thursday to the US House of Representatives Select Committee on China, OpenAI said that DeepSeek had used so-called distillation techniques as part of “ongoing efforts to free-ride on the capabilities developed by OpenAI and other US frontier labs.” The company said it had detected “new, obfuscated methods” designed to evade OpenAI’s defenses
NEW IMPORTS: Car dealer PG Union Corp said it would consider introducing US-made models such as the Jeep Grand Cherokee and Stellantis’ RAM 1500 to Taiwan Tesla Taiwan yesterday said that it does not plan to cut its car prices in the wake of Washington and Taipei signing the Agreement on Reciprocal Trade on Thursday to eliminate tariffs on US-made cars. On the other hand, Mercedes-Benz Taiwan said it is planning to lower the price of its five models imported from the US after the zero tariff comes into effect. Tesla in a statement said it has no plan to adjust the prices of the US-made Model 3, Model S and Model X as tariffs are not the only factor the automaker uses to determine pricing policies. Tesla said
China’s top chipmaker has warned that breakaway spending on artificial intelligence (AI) chips is bringing forward years of future demand, raising the risk that some data centers could sit idle. “Companies would love to build 10 years’ worth of data center capacity within one or two years,” Semiconductor Manufacturing International Corp (SMIC, 中芯) cochief executive officer Zhao Haijun (趙海軍) said yesterday on a call with analysts. “As for what exactly these data centers will do, that hasn’t been fully thought through.” Moody’s Ratings projects that AI-related infrastructure investment would exceed US$3 trillion over the next five years, as developers pour eye-watering sums
Australian singer Kylie Minogue says “nothing compares” to performing live, but becoming an international wine magnate in under six years has been quite a thrill for the Spinning Around star. Minogue launched her first own-label wine in 2020 in partnership with celebrity drinks expert Paul Schaafsma, starting with a basic rose but quickly expanding to include sparkling, no-alcohol and premium rose offerings. The actress and singer has since wracked up sales of around 25 million bottles, with her carefully branded products pitched at low-to mid-range prices in dozens of countries. Britain, Australia and the United States are the biggest markets. “Nothing compares to performing
RSS